These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3066667)

  • 1. Liposomes as carriers for a human malaria sporozoite vaccine.
    Richards RL; Hayre MD; Hockmeyer WT; Alving CR
    Biochem Soc Trans; 1988 Dec; 16(6):921-2. PubMed ID: 3066667
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a sporozoite malaria vaccine.
    Nussenzweig V; Nussenzweig RS
    Am J Trop Med Hyg; 1986 Jul; 35(4):678-88. PubMed ID: 2425647
    [No Abstract]   [Full Text] [Related]  

  • 3. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Luo K; Zavala F; Gordy J; Zhang H; Markham RB
    Vaccine; 2017 Apr; 35(18):2358-2364. PubMed ID: 28342669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in malaria research: parasite biology, chemotherapy and host/parasite relationships.
    Trigg PI
    Ann Ist Super Sanita; 1985; 21(3):271-90. PubMed ID: 3914847
    [No Abstract]   [Full Text] [Related]  

  • 5. Malaria vaccine: the effect of sporozoite-induced immunity on exo-erythrocytic stages.
    Bafort JM; Pryor WH; Beaudoin RL
    Ann Soc Belg Med Trop; 1978; 58(1):63-4. PubMed ID: 354537
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasmodium berghei circumsporozoite protein encapsulated in oligomannose-coated liposomes confers protection against sporozoite infection in mice.
    Terkawi MA; Kuroda Y; Fukumoto S; Tanaka S; Kojima N; Nishikawa Y
    Malar J; 2014 Nov; 13():426. PubMed ID: 25373617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates.
    Annoura T; Ploemen IH; van Schaijk BC; Sajid M; Vos MW; van Gemert GJ; Chevalley-Maurel S; Franke-Fayard BM; Hermsen CC; Gego A; Franetich JF; Mazier D; Hoffman SL; Janse CJ; Sauerwein RW; Khan SM
    Vaccine; 2012 Mar; 30(16):2662-70. PubMed ID: 22342550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parasitology. Malaria vaccines: back to the future?
    Waters AP; Mota MM; van Dijk MR; Janse CJ
    Science; 2005 Jan; 307(5709):528-30. PubMed ID: 15681372
    [No Abstract]   [Full Text] [Related]  

  • 9. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
    Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
    Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative approach to malaria vaccine with a permanent attenuated mutant from a high virulence Plasmodium berghei strain.
    Suzuki M; Waki S; Igarashi I; Takagi T; Miyagami T; Nakazawa S
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 May; 264(3-4):319-25. PubMed ID: 3310458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development.
    Egan JE; Weber JL; Ballou WR; Hollingdale MR; Majarian WR; Gordon DM; Maloy WL; Hoffman SL; Wirtz RA; Schneider I
    Science; 1987 Apr; 236(4800):453-6. PubMed ID: 3551073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2.
    Saul A; Lord R; Jones GL; Spencer L
    J Immunol; 1992 Jan; 148(1):208-11. PubMed ID: 1727867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Malaria in the municipality of Humaitá, State of Amazonas. V - Serological aspects of Plasmodium falciparum and Plasmodium berghei antigens].
    Salata E; Correa FM; Sogayar R; Ramos MA; Meira DA; Barraviera B; Vadileti C; Pirolla JA
    Rev Inst Med Trop Sao Paulo; 1981; 23(5 Suppl 5):32-6. PubMed ID: 7046014
    [No Abstract]   [Full Text] [Related]  

  • 14. [Malaria vaccine research].
    Sellioğlu B
    Mikrobiyol Bul; 1986 Jan; 20(1):37-41. PubMed ID: 3523172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sporozoite immunity and vaccine development.
    Hockmeyer WT; Ballou WR
    Prog Allergy; 1988; 41():1-14. PubMed ID: 3043419
    [No Abstract]   [Full Text] [Related]  

  • 16. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP1(42).
    Weiss R; Gabler M; Jacobs T; Gilberger TW; Thalhamer J; Scheiblhofer S
    Vaccine; 2010 Jun; 28(28):4515-22. PubMed ID: 20438877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved efficacy of doxycycline in liposomes against Plasmodium falciparum in culture and Plasmodium berghei infection in mice.
    Rajendran V; Singh C; Ghosh PC
    Can J Physiol Pharmacol; 2018 Nov; 96(11):1145-1152. PubMed ID: 30075085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary results in malaria control by a sporozoite vaccine].
    Wagner WH
    Arzneimittelforschung; 1987 Dec; 37(12):1417. PubMed ID: 3329517
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimate of Plasmodium falciparum sporozoite content of Anopheles stephensi used to challenge human volunteers.
    Davis JR; Murphy JR; Clyde DF; Baqar S; Cochrane AH; Zavala F; Nussenzweig RS
    Am J Trop Med Hyg; 1989 Feb; 40(2):128-30. PubMed ID: 2645802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of Genetically Arrested Parasites (GAPs) For a Precision Malaria Vaccine.
    Kreutzfeld O; Müller K; Matuschewski K
    Front Cell Infect Microbiol; 2017; 7():198. PubMed ID: 28620583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.